UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 3, 2009
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
5.02
|
DEPARTURE
OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF
CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
|
On August
31, 2009, Oramed Pharmaceuticals Inc. (“Oramed”), through its Israeli
subsidiary, Oramed Ltd., entered into an amendment to the employment agreement
of Yifat Zommer, Oramed’s Chief Financial Officer, Treasurer and Secretary (the
"Amendment"). Pursuant to the Amendment, Ms. Zommer will no longer be
employed on a part-time basis of 80%, but will rather be a full-time employee
(at least 45 hours a week) and will receive a gross monthly salary of NIS
22,000, an increase of 25%. In accordance with the employment agreement, as
amended, as of October 19, 2009, Ms. Zommer’s gross monthly salary will be NIS
24,200, a 10% increase.
A copy of
the Amendment is attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference.
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On
September 3, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing
that its Chief Executive Officer, Nadav Kidron will present at the Rodman &
Renshaw’s 11th Annual
Healthcare Conference on Friday September 11, 2009 at 10:00 a.m. EDT at the New
York Palace Hotel in New York City.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.2
and is incorporated by reference herein.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated September 3, 2009.
|
|
|
|
99.2
|
|
Amendment
to Employment Agreement by and between Oramed Ltd. and Yifat Zommer
entered into as of August 31,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
Dated:
September 3, 2009
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
Nadav
Kidron
|
|
|
President,
CEO and Director
|
Exhibit
Index
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated September 3, 2009.
|
|
|
|
99.2
|
|
Amendment
to Employment Agreement by and between Oramed Ltd. and Yifat Zommer
entered into as of August 31,
2009.
|